Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
Myriad Genetics, Inc. MYGN is making notable strides in its key strategic areas, which is poised to help it grow in the upcoming quarters. New product introductions and enhancements are gaining traction with customers. There is growing optimism about the company’s huge potential in the oncology space. Meanwhile, the impacts of macroeconomic pressure and fierce rivalry can be worrisome for Myriad Genetics’ performance.
In the past year, this Zacks Rank #3 (Hold) company has outperformed both the industry and the S&P 500 composite. Shares have surged 63.8% compared with the industry’s 0.7% rise and the S&P 500’s gain of 25.7%.
The renowned genetic testing and precision medicine company has a market capitalization of $2.51 billion. MYGN’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 213.4%.
Let’s delve deeper.
Tailwinds for MYGN
Progress With Three Strategic Priorities: Myriad Genetics is advancing in developing top-quality products, building new enterprise capabilities and executing key initiatives to drive long-term growth and profitability. MYGN is gaining shares in the hereditary cancer market. The prenatal business grew 25% year over year in the second quarter of 2024, with a 12% increase in testing volumes due to ongoing initiatives to improve average selling prices (ASPs).GeneSight revenues increased 22% from the comparable 2023 period on nearly 129,000 tests in the second quarter.
Myriad Genetics announced several new strategic partnerships, including a collaboration with the National Cancer Center Hospital East in Japan to study the prognostic and predictive value of molecular residual disease (MRD) testing. It focuses its capital on new tech-enabled tools and capabilities, innovation and commercial capabilities that will improve the customer experience, such as the Labs of the Future program.
Product Launches and Upgrades: Myriad Genetics continues to gain customer acceptance for its slew of products. In June 2024, the company launched the Foresight Carrier Screening test with a new Universal Plus Panel. The anticipated guideline expansion by the American College of Obstetricians and Gynecologists for carrier screening is likely to broaden the market opportunity for this test and drive increased adoption and revenue per test improvements.
Earlier this year, the company received a patent from the United States Patent and Trademark Office, which bolsters its ability to deliver a tumor-informed, high-definition MRD assay to the market. It also made enhancements to the GeneSight Psychotropic test — a pharmacogenomic test for mental health medications — in 2023.
Huge Potential in Oncology Testing: Myriad Genetics has identified the key opportunities to grow its Oncology business by expanding companion diagnostics, capturing markets through new clinical guidelines and introducing new offerings. In the second quarter of 2024, growth in hereditary cancer testing revenues reflected the company’s ongoing efforts to improve average revenue per test by expanding payer coverage and improving revenue cycle processes, which are helping reduce the no-pay rate. The addition of Intermountain Precision Genomics has broadened its oncology testing options, bringing Precise Tumor and Precise Liquid tests in-house.
As part of the strategic reorganization of its European operations, the company has sold its EndoPredict business to Eurobio Scientific, giving the right to sell Prolaris in vitro diagnostic kits outside of the United States. The reorganization and sale are expected to boost MYGN’s adjusted operating income annually by more than $4 million by streamlining the cost structure. The development of the Precise MRD assay also advances.
Factors Weighing on MYGN
Macroeconomic Concerns: With active operations internationally, the company is prone to several regulatory, political, operational, financial and economic risks. The curtailment of trade and other business restrictions and global inflationary pressure can result in higher costs of retaining skilled employees, producing test results and procuring lab supplies, denting its profitability. In the second quarter, Penumbra recorded a 4% jump in selling, general and administrative expenses due to a $2.6 million increase in compensation costs.
Increasing Competition: Myriad Genetics is currently facing growing competition in its key BRACAnalysis market as more players make their entry. The company expects the rivalry to intensify, with other companies potentially launching molecular diagnostic tests. In our opinion, competitive headwinds might push down prices for the high-priced tests provided by Myriad Genetics. This might deter margin improvement in the future.
MYGN Estimate Trend
In the past 30 days, the Zacks Consensus Estimate for the company’s 2024 earnings has increased 11.1% to 10 cents.
The Zacks Consensus Estimate for 2024 revenues is pegged at $840.3 million, suggesting an 11.6% rise from the year-ago reported number.
Top MedTech Stocks
Some better-ranked stocks in the broader medical space are TransMedix Group TMDX, AxoGen AXGN and Boston Scientific BSX. While TransMedix Group currently sports a Zacks Rank #1 (Strong Buy), AxoGen and Boston Scientific each carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
TransMedix Group’s earnings are expected to surge 259.7% in 2024. Its shares have soared 156.5% compared with the industry’s 17.5% rise in the past year.
TMDX’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 287.5%.
AxoGen has an estimated 2024 earnings growth rate of 94.1% compared with the industry’s 12.8%. Shares of the company have soared 165.9% compared with the industry’s 17.6% rise over the past year.
AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%.
Boston Scientific has an estimated earnings growth rate of 17.1% compared with the industry’s 14.9%. Shares of the company have rallied 57.5% compared with the industry’s 19.5% rise over the past year.
BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.
Zacks Investment Research
Alameda, CA-based Penumbra, Inc. PEN has secured the CE Mark in Europe for its newest computer-assisted vacuum thrombectomy (CAVT) technologies, Lightning Flash 2.0 and Lightning Bolt 7. Lightning Flash 2.0 is the most advanced mechanical thrombectomy system available to address venous and pulmonary thrombus while the Lightning Bolt 7 stands out as the most powerful arterial thrombectomy system in the market.
The latest innovations further enhance the company’s neuro and vascular portfolios.
Likely Trend of PEN Stock Following the Announcement
Following the news, shares of PEN inched up 0.4% to $187.65 at yesterday’s close. With thrombectomy procedures gaining fast popularity globally, Penumbra has been witnessing market share gains, banking on strong customer uptake of its Lightning Bolt and Flash lines.
The latest development is likely to boost European physicians’ trust in considering CAVT as a valuable first-line option to manage conditions such as pulmonary embolism (PE), venous thrombosis and other severe cases. Henceforth, we expect the market sentiment toward the stock to remain positive, driven by this development.
More on Penumbra’s Latest CAVT Technologies
Lightning Flash 2.0 features Penumbra’s Lightning Intelligent Aspiration technology with the latest dual clot detection algorithms, using both pressure and flow-based processes to detect blood clots and blood flow. The catheter is made with MaxID hypotube technology, allowing an inner diameter similar to large-bore catheters while maintaining a lower profile and a soft, atraumatic tip design.
The design facilitates the removal of blood clots with speed, safety and simplicity, allowing physicians to navigate the body’s complex anatomy and deliver high-power aspiration for clot removal with minimal blood loss.
Lightning Bolt 7 uses a new method for removing blood clots called modulated aspiration, which pairs the Lightning Intelligent Aspiration technology with an advanced microprocessor algorithm. When combined, the system is designed to rapidly remove large, fibrous blood clots in the arteries with minimal blood loss, addressing conditions such as acute limb ischemia , hibernating thrombus and visceral occlusions.
Lightning Bolt 7 is engineered to detect the difference between blood clots and blood flow. Additionally, it is designed to break the friction between the catheter and clot by having the computer algorithms rapidly modulate aspiration to quickly fatigue the thrombus and remove the clot from the arteries.
Industry Prospects Favoring Penumbra
A report from Precedence Research valued the thrombectomy devices market at $1.52 billion in 2023 and predicted it to witness a compound annual growth rate of 7.33% through 2033.
The market growth is fueled by the rising incidences of cardiovascular diseases among an aging population, leading to an increasing demand for thrombectomy procedures. Additionally, the devices help prevent life-threatening diseases like stroke, PE and heart attack, among others.
Penumbra’s Other Developments
In June 2024, Penumbra announced the CE Mark and European launch of two advanced neuro access offerings, BMX 81 and BMX 96, designed for neurovascular management of ischemic and hemorrhagic stroke. The announcement follows the launch of three new RED reperfusion catheters (RED 43, RED 72 with SENDit Technology and RED 78) earlier in May.
PEN Stock’s Price Performance
In the past year, PEN’s shares have declined 29.4% against the industry’s 17.6% growth.
PEN’s Zacks Rank and Key Picks
Penumbra currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the broader medical space are Boston Scientific BSX, AxoGen AXGN, and SiBone SIBN, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have risen 57.5% in the past year. Estimates for the company’s earnings per share have remained constant at $2.40 in 2024 and $2.71 in 2025 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for AxoGen’s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 165.9% in the past year compared with the industry’s 17.6% growth. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for SiBone’s 2024 loss per share have remained constant at 89 cents in the past 30 days. Shares of the company lost 31.4% in the past year against the industry’s 17.6% growth. SIBN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.
Zacks Investment Research
Inspira Technologies OXY B.H.N. Ltd. IINN has secured an additional U.S. Patent approval for the VORTX orbiting blood oxygenation delivery system, a fundamental technology of the INSPIRA ART (Augmented Respiration Technology) device. With this addition, the total number of claims deemed novel relating to the core technology of the device comes to 32.
The latest development advances blood oxygenation technologies, marking another crucial milestone for the company and underscoring the core technological capabilities of the INSPIRA ART.
Following the news, shares of IINN jumped 5.2% to $1.21 at Friday’s close. Inspira is working on new life support-extending technologies with blood oxygenation and blood monitoring technologies, aiming to transform the respiratory treatment space. We expect the market sentiment toward the stock to remain positive around this development.
Significance of IINN’s INSPIRA ART Device Featuring VORTX
The VORTX system aims to oxygenate blood without fiber membranes, starkly differing from the existing fiber technologies for blood oxygenation. The traditional fiber oxygenators force blood to flow through multiple fiber layers, causing harmful turbulence, friction and shear forces. Due to the fiber fabric's high resistance to blood flow, it creates pressure differences that can severely damage blood components, causing hemolysis, white blood cell damage, inflammatory and immune system activation and blood clotting.
IINN’s INSPIRA ART device can make a major impact on the $19 billion mechanical ventilation market. It offers a potential alternative to nearly 20 million intensive care unit patients with respiratory failure each year, with many relying on mechanical ventilators, by maintaining stable oxygen saturation levels without the need for ventilators while allowing patients to remain awake during treatment. Equipped with HYLA real-time continuous blood monitoring technology, the system can rapidly detect changes in patient conditions so that physicians can make more informed decisions.
Inspira had obtained the FDA’s 510(k) clearance for the INSPIRA ART100 system for use in Cardiopulmonary Bypass procedures, along with the Israeli AMAR (Medical Device Division of the Israeli Ministry of Health) certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures. More products are currently in the development phase, including the INSPIRA ART500 or Gen 2, the INSPIRA Cardi-ART portable modular device and the HYLA blood sensor.
Industry Prospects Favoring Inspira
A Data Bridge Market Research report valued the global oxygen delivery system market at $12.94 billion in 2021, forecasted to witness a compound annual growth rate of 6.3% through 2029.
The market growth is expected to be driven by the growing prevalence of diseases such as obesity, hypertension, chronic obstructive pulmonary disease (COPD), asthma, respiratory distress syndrome, pneumonia, cystic fibrosis and associated complications in cardiac arrest. Developed healthcare infrastructure and expanded insurance coverage globally should boost the market.
Recent Developments Within Inspira
Last month, Inspira secured the FDA’s listing for the INSPIRA CART, which has been tailored for use with the INSPIRA ART100 system. The INSPIRA CART is designed for use in operating rooms during Cardiopulmonary Bypass procedures in the United States. It is currently classified as a Class I Medical Device and 510(K) Exempt under the FDA code for cardiopulmonary bypass accessory equipment.
IINN Price Performance
In the past year, IINN shares have fallen 19.4% against the industry’s 17.6% growth.
IINN’s Zacks Rank and Key Picks
Inspira currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Boston Scientific BSX, AxoGen AXGN and SiBone SIBN, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have risen 57.2% in the past year. Estimates for the company’s earnings per share have remained constant at $2.40 in 2024 and $2.71 in 2025 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for AxoGen’s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 156.8% in the past year compared with the industry’s growth of 17.6%. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for SiBone’s 2024 loss per share have remained constant at 89 cents in the past 30 days. Shares of the company have dropped 30.5% in the past year against the industry’s 17.6% growth. SIBN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.
Zacks Investment Research
Inogen, Inc. INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid first-quarter 2024 performance and a strong product portfolio, seems justified. However, issues like stiff competition and forex volatility are major downsides.
The Zacks Rank #2 (Buy) company’s shares have risen 106.4% year to date compared with 9.2% growth of the industry. The S&P 500 has increased 17.7% during the same time frame.
The renowned provider of POCs has a market capitalization of $268.7 million. The company projects 56.6% growth for 2024 and expects to witness continued improvements in its business. Inogen’s P/S ratio of 0.8X makes its valuation attractive compared with the industry’s 3.1X.
Let us delve deeper.
High Prospects in the POC Space: We are optimistic about the POCs’ superiority over conventional oxygen therapy (known as the delivery model). Inogen primarily develops, manufactures and markets innovative POCs to deliver supplemental long-term oxygen therapy (LTOT) to patients suffering from chronic respiratory conditions.
INGN’s proprietary Inogen One and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen anytime, anywhere, with a battery that can be plugged into an outlet. Per a report by Data Bridge Market Research, the POCs market was valued at $1.58 billion in 2022 and is anticipated to reach $3.03 billion by 2030 at a CAGR of 8.5%.
Product Portfolio: We are optimistic about Inogen’s expanding product portfolio. The company has received the FDA 510(k) clearance for the Inogen Rove 4, which is set to be launched soon. The Rove 4 will offer patients a new flow setting compared to the earlier versions, a service life of up to eight years and highest oxygen production. It is also the lightest POC in the market.
Inogen launched Rove 6 in the U.S. market in July 2023. The Inogen Rove 6 is the first POC with an expected service life of eight years.
Strong Q2 Results: Inogen’s robust year-over-year uptick in domestic and international business-to-business sales buoys optimism. Solid year-over-year top and bottom-line performances were encouraging. Further, the expansion of the adjusted gross margin bodes well.
On the earnings call, management confirmed that targeting hospitals in addition to individual practitioners through its rental business gave earlier access to patients in their care pathway, increasing the duration over which INGN can receive payments. By expanding its scale, efficiency and throughput in the rental channel, Inogen expects to drive higher profitability over time.
The company is also seeing cost benefits in the form of lower sales and marketing expenses on the back of the recent exit of its third-party relationship in the rental channel. These factors raise optimism about the stock.
Risks
Stiff Competition: The LTOT market has intense industrial competition. Inogen faces competition from several POC producers and distributors as well as suppliers of other LTOT services, such as home delivery of oxygen cylinders or tanks. Given the relatively straightforward regulatory path in the oxygen therapy device manufacturing market, Inogen expects the industry to become increasingly competitive in the future.
Forex Volatility: The foreign market accounts for a sizeable amount of INGN's income. Management anticipates overseas revenues to continue to be erratic due to the distributor's size and timing. In the near future, INGN also expects unfavorable foreign exchange rates to hinder revenue growth since the U.S. dollar is increasing relative to the euro and other foreign currencies.
Estimate Trend
Inogen has been witnessing an improving estimate revision trend for 2024. In the past 60 days, the Zacks Consensus Estimate for its loss per share has narrowed 11.4% to $1.95.
The Zacks Consensus Estimate for 2024 revenues is pegged at $327 million, suggesting a 3.6% decline from the year-ago reported number.
Inogen, Inc Price
Inogen, Inc price | Inogen, Inc Quote
Key Picks
Some other top-ranked stocks in the broader medical space are Boston Scientific BSX, AxoGen AXGN and SiBone SIBN, each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have risen 58.4% in the past year. Estimates for the company’s earnings per share have remained constant at $2.40 for 2024 and $2.71 for 2025 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for AxoGen’s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 145% in the past year compared with the industry’s growth of 15.5%. AXGN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for SiBone’s 2024 loss per share have remained constant at 89 cents in the past 30 days. Shares of the company have lost 30.4% in the past year against the industry’s 15.5% growth. SIBN’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.
Zacks Investment Research
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.